Mon, March 5, 2012
[ Mon, Mar 05th 2012 ] - Market Wire
Sienna Gold Warrants Extended
[ Mon, Mar 05th 2012 ] - Market Wire
30 a.m. ET
Fri, March 2, 2012
Thu, March 1, 2012
Wed, February 29, 2012
Tue, February 28, 2012
[ Tue, Feb 28th 2012 ] - Market Wire
Alere to Acquire eScreen, Inc.
[ Tue, Feb 28th 2012 ] - Market Wire
ICON Acquires PriceSpective
Mon, February 27, 2012
Sat, February 25, 2012
Fri, February 24, 2012
[ Fri, Feb 24th 2012 ] - Market Wire
BrainStorm Featured on CNBC
Thu, February 23, 2012
[ Thu, Feb 23rd 2012 ] - Market Wire
00 am ET
Wed, February 22, 2012
Tue, February 21, 2012
[ Tue, Feb 21st 2012 ] - Market Wire
Black Smoker Corporate Update

Oncothyreon Announces Full Year and Fourth Quarter 2011 Financial Results Conference Call


//health-fitness.news-articles.net/content/2012/ .. rter-2011-financial-results-conference-call.html
Published in Health and Fitness on Tuesday, February 28th 2012 at 5:15 GMT by Market Wire   Print publication without navigation


Oncothyreon Announces Full Year and Fourth Quarter 2011 Financial Results Conference Call

Oncothyreon Announces Full Year and Fourth Quarter 2011 Financial Results Conference Call

[ ]

SEATTLE, Feb. 28, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: [ ONTY ]) today announced that it will conduct a conference call to discuss its full year and fourth quarter 2011 financial results and provide a review of its pipeline of products in development on Tuesday, March 6, 2012 at 4:30 p.m. Eastern Time.

To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the "Events" page of the "News & Events" section of Oncothyreon's website at [ www.oncothyreon.com ]. An archive of the webcast will be available after completion of the discussion and will be posted on the Oncothyreon website.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit [ www.oncothyreon.com ].

SOURCE Oncothyreon Inc.

[ Back to top ]


Publication Contributing Sources